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Summary. The occurrence of  cytotoxic lymphocyte 
subpopulations (i.e., CD 16 ÷, CD57 ÷ and cytotoxic 
CD 8 ÷) was studied in the peripheral blood of  18 
B-cell chronic lymphocytic leukemia (B-CLL) pa- 
tients. The absolute numbers of CD 57 ÷, CD 16 ÷ and 
cytotoxic CD 8 ÷ lymphocytes were increased in the 
peripheral blood of  untreated patients as compared 
with healthy donors, suggesting a causal relation 
with the accumulation of malignant B-cells. For 5 
B-CLL patients and 5 hematological normal donors, 
the lymphocyte subpopulations in peripheral 
blood, lymph nodes and bone marrow were deter- 
mined. A significant immune response was observ- 
ed in the lymph nodes of the patients, as reflected 
by the CD 3 ÷ lymphocytes, which were 1.7 -27  times 
larger in the patients lymph nodes than in their 
peripheral blood and bone marrow. In contrast, 
with peripheral blood this was mainly caused by an 
increase in CD 4 + lymphocytes. The CD 57 lympho- 
cytes in the lymph nodes of the patients had abnor- 
mal orthogonal light-scattering signals and an ab- 
normal density of CD 57 ÷ receptors in comparison 
with their peripheral blood CD 57 ÷ lymphocytes or 
the CD57 ÷ lymphocytes in the peripheral blood, 
bone marrow and tonsils of the hematological nor- 
mal donors. This study shows that although a signi- 
ficant increase of cytotoxic lymphocytes in the peri- 
pheral blood of B-CLL patients is observed, the 
actual distributions of the non-malignant lympho- 
cytes can be quite different at the actual tumor sites, 
i.e., bone marrow and lymph nodes. 
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Introduction 
B-cell chronic lymphocytic leukemia (B-CLL) is 
characterized by a progressive accumulation of 
malignant B lymphocytes. In addition, several 
phenotypic and functional abnormalities of the 
T-lymphocyte population are described. The num- 
ber of CD4-positive (CD4 ÷) lymphocytes is de- 
creased, whereas the number of  CD8-positive 
(CD 8 ÷) lymphocytes i increased, both relative to 
what is found in healthy donors [2,8,14-16,19].  
Moreover, the CD8 ÷ lymphocytes in B-CLL pa- 
tients mainly consist of cytotoxic CD 8 ÷ lympho- 
cytes [22]. A large percentage of  the CD 4 ÷ lympho- 
cytes coexpress NK lineage markers [24]. Also, the 
CD 57 antigen is present on a significantly higher 
part of the T-lymphocytes in B-CLL patients in 
comparison with healthy donors [5]. Functional 
studies on T lymphocytes from B-CLL patients give 
contradictory results [1,3,4, 6, 7, 9 -13,  17, 18]. 
As cytotoxic lymphocytes may have a destructive 
effect on malignant B lymphocytes, it is of impor- 
tance to know the composit ion of the cytotoxic lym- 
phocyte population in the different blood compart- 
ments. Therefore, we have analyzed cytotoxic lym- 
phocyte subpopulations i  the peripheral blood, 
bone marrow and lymph nodes of normal donors 
and B-CLL patients. 
Materials and methods 
Patients and controls. The study included 18 patients with 
B-CLL, with a mean age of 60 years (range 41-85). The pa- 
tients were graded using the Rai clinical staging system. Six pa- 
tients were included with Rai stage 0 with stable disease for at 
least 2 years. Four patients graded stage 0 were in partial remis- 
sion after splenic irradiation a d/or chemotherapy and gluco- 
eorticosteroid treatment. These patients were treated because of 
progressive disease (Rai stages III, IV) and received main- 
tenance treatment with chlorambucil and prednisolone. An- 
other six patients with progressive disease (Rai stages II, III, IV) 
who had previously been untreated and two patients graded Rai 
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stage IV who were refractory to chemotherapy and glucocorti- 
costeroid treatment were included. The control group included 
30 healthy individuals who were from 22 to 90 years of age. Pe- 
ripheral blood and bone marrow aspirates were obtained from 
5 normal adults. Tonsils obtained after tonsillectomy of hema- 
tological healthy donors were used as controls for the lymph 
nodes. 
Preparation of lymphocytes. Peripheral blood was collected 
by venipuncture into vacutainer tubes containing heparin as 
anticoagulant (150 USP IU sodium heparin/10 ml; Venoject 
Terumo Europe). The absolute number of peripheral blood lym- 
phocytes was determined with a H 6000 (Technicon, Tarrytown, 
NY). The absolute number of lymphocyte subpopulations was 
obtained using this number. Bone marrow aspirates were col- 
lected using heparin as anticoagulant. Lymphocytes were ob- 
tained after density separation (density 1,077 g/cm 3, Percoll 
Pharmacia Fine Chemicals, Uppsala, Sweden) [20]. Four cervi- 
cal lymph nodes and one lymph node from the groin were re- 
moved surgically under local anesthesia. The lymph nodes 
varied in diameter from 2-5  cm. The lymph nodes and tonsils 
were put in a solution of minimal essential medium (MEM, 
Flow Laboratories, Irvine, Scotland) containing 10% fetal calf 
serum (FCS, GIBCO, Paisley, Scotland) and 106 IU Penicillin 
G/L (Pen). The lymph nodes and tonsils were cut on a polyester 
mesh (pore diameter 30/zm, Visprox BV, Haarlem, The Nether- 
lands), using scissors and tweezers. During preparation, the 
lymph nodes were continuously rinsed with MEM containing 
FCS and Pen. The cell suspension was washed 3 times with 
MEM at 200 g for 5 min. For each patient peripheral blood, 
bone marrow and lymph nodes were collected and processed on 
the same day. The lymphocyte suspensions were adjusted to a 
concentration of 1.107 lymphocytes/ml with phosphate-buffered 
saline containing 0.05% sodium azide and 1°70 bovine serum 
albumin (PBS). 
Lymphocyte subset identification. Lymphocytes were incubated 
with an optimal concentration of fluorescently labeled mono- 
clonal antibodies. The labeled lymphocytes were resuspended in 
PBS to a final concentration of 106 lymphocytes/ml. The fol- 
lowing monoclonal antibodies were used: CD3 (anti-Leu4 
FITC, PE), CD 4 (anti-Leu 3 FITC), CD 8 (anti-Leu 2a FITC, 
PE), CD 16 (anti-Leu l la FITC) and CD 57 (anti-Leu7 FITC). 
The Mabs were purchased from Becton Dickinson (San Jose, 
Calif.). Flow cytometric analysis was performed within 8 h after 
sample collection to preserve both the optimal binding of 
monoclonal antibody and light-scattering properties of 
lymphocytes. The flow cytometer (FCM) used is described in 
detail elsewhere [20]. By adjustment of the FCM with standard 
microspheres, reproducible apparatus conditions were obtained 
for the measurement of light scattering and fluorescence inten- 
sity [21]. Residual monocytes, contaminating the lymphocyte 
preparation were excluded from the measured ata by discrimi- 
nation on forward and orthogonal light scattering in the FCM 
[21]. Discrimination levels of fluorescence staining were chosen, 
so that less than 0.02% of the cells of a control sample fell 
above the level. 
Orthogonal ight-scatter histograms of the CD8-positive 
(CD 8 +) lymphocytes were obtained after gating on the fluore- 
scence intensity of the immunofluorescent-labeled c lls. The 
CD 8 + lymphocytes were divided into suppressor (CD 8a ÷) lym- 
phocytes and cytotoxic (CD 8b ÷) lymphocytes by dividing the 
orthogonal light scatter histogram of CD 8 ÷ lymphocytes into 
two components [20]. CD 8a ÷ lymphocytes have a low orthogo- 
nal light-scattering signal whereas CD 8b ÷ lymphocytes have a 
high orthogonal light-scattering signal [20]. Each measurement 
contained at least 40,000 lymphocytes. 
Results 
Lymphocyte subpopulations inperipheral blood 
The absolute numbers of lymphocytes positive with 
the monoclonal antibodies, CD 57 and CD 16 were 
determined in the peripheral blood of 18 B-CLL 
patients and 30 healthy donors. In addition, the 
absolute numbers of CD 8 + cytotoxic lymphocytes 
(CD 8b ÷) were determined as described in Materials 
and methods. The absolute number of CD8b ÷, 
CD 57 + and CD 16 + lymphocytes of B-CLL patients 
were significantly different from those of healthy 
controls: P < 0.0001, P < 0.00001 and P < 0.000001, 
respectively (Kruskal Wallis test). In Fig. 1 the abso- 
lute numbers of the three lymphocyte subpopula- 
tions are given. The absolute number of cytotoxic 
lymphocyte populations in the B-CLL patients has 
a broad distribution, as compared with healthy 
donors. The total lymphocyte count of the B-CLL 
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F ig . la -c .  Absolute number of CD8b ÷ (a), CD57 ÷ (b) and 
CD 16 ÷ lymphocytes (e) in the peripheral blood of 18 B-CLL 
patients ubdivided by Rai clinical stage; stage 0 -  ( -  no treat- 
ment), 0+ (+ on therapy), I I - ,  I I I - ,  IV-, IV+ and 30 healthy 
controls (e). Numbers are given on a logarithmic scale and mean 
values are indicated as horizontal bars in the figures. Statistical 
evaluation of the data according to the two-sided Wilcoxon test 
showed significant differences between the results obtained for 
the following groups: a 0 -  and controls (P < 0.002); I I - ,  I I I - ,  
IV-  and controls (P < 0.0002); 0+ and I I - ,  I I I - ,  IV -  
(P < 0.01) b 0 -  and controls (P < 0.0002); I I - ,  I l l - ,  IV-  
and controls (P < 0.0002); 0+ and controls (P < 0.03); 0+ 
and I I - ,  I I I - ,  IV -  (P < 0.01) e 0 -  and controls (P < 0.02); 
0+ and I I - ,  I I I - ,  IV -  (P < 0.0002); 0 -  and 0+ (P < 0.01); 
I I - ,  I l l - ,  IV -  and 0+ (P < 0.01) 
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patients did not correlate significantly with the ab- 
solute number of CD 8b*, CD 57+ and CD 16" lym- 
phocytes (r 2 -- 0.35, 0.24 and 0.34, respectively). 
Subdivision into different disease stages revealed 
that untreated patients with progressive disease had 
an increased absolute number of  CD 8b ÷, CD 57* 
and CD 16* lymphocytes as compared with healthy 
donors. Untreated patients with benign disease 
showed normal  or increased absolute numbers of  
cytotoxic lymphocytes for the three subpopulations. 
A remarkable observation is that treated patients, 
graded Rai stage 0, had decreased absolute numbers 
of CD 16 ÷ lymphocytes, whereas the number of 
CD8b ÷ and CD57+ lymphocytes were within the 
normal  range for these patients. 
Lymphocyte subpopulations in the bone marrow 
and lymph nodes 
The percentage of cells positive with the monoclo-  
nal antibodies CD 3, CD 4, CD 8, CD 57 and CD 16 
were determined in the peripheral blood, bone mar-  
row and lymph nodes of five patients graded Rai 
stages II, I I I  and IV and five controls. Whereas the 
results obtained from peripheral blood and bone 
marrow could be compared with those found in 
normal  donors, no normal lymph node material 
could be obtained from these donors. To obtain an 
indication of the distribution of lymphocyte sub- 
populations in lymphoid tissue, we chose tonsils as 
the control material for the patients' lymph nodes. 
The data are presented in Table 1. Compared to the 
control group, the percentages of lymphocyte sub- 
populations in the peripheral blood and bone mar-  
row of the patients are considerably lower due to 
the overwhelming number of mal ignant B cells. In 
contrast, in the peripheral blood and bone marrow, 
the percentage of CD 3* lymphocytes was remarkab- 
ly large in the lymph nodes of the patients. A large 
variation in the percentage of CD3* lymphocytes 
was found in the tonsils; the remaining cells were 
primari ly B lymphocytes (CD 19"). Interestingly, in 
the patients' lymph nodes, all the CD 3* lympho- 
cytes could be accounted for by CD4* and CD 8+ 
lymphocytes, which was not the case for the CD 3* 
lymphocytes in the tonsils. For a more detailed ana- 
lysis of  the non-mal ignant cells, the CD 4", CD 8 ÷, 
CD57* and CD 16" cells were normalized on the 
CD3 ÷ lymphocytes in the same blood compart -  
ment. The results are shown Fig. 2 a -  d, respectively. 
The results from the tonsils were obtained f rom dif- 
ferent donors and are shown in a separate column. 
Furthermore, the mean ratios and standard devia- 
tion of  the peripheral blood cell populat ions of 30 
healthy donors are given in a separate column. 
In all patients, the CD 4 /CD 3 ratio was larger in 
lymph nodes in comparison with the peripheral 
blood. In contrast, CD4/CD3 ratios were clearly 
lower in tonsils as compared with peripheral blood 
CD 4 /CD 3 ratios in healthy donors. A large varia- 
tion in the CD 4 /CD 3 ratio was found in the bone- 
marrow aspirates of patients and controls. 
No difference was found between the peripheral 
blood CD 8/CD 3 ratio of patients and controls. In 
the patients, the bone-marrow CD8/CD3 ratios 
were lower than peripheral b lood CD 8/CD 3 ratios, 
whereas the opposite was observed for the control 
group. The CD 8/CD 3 ratios of the patients' lymph 
nodes were undoubtedly lower than the peripheral 
blood and bone-marrow CD8/CD3 ratios, but 
within the range found in the tonsils. 
Table 1. Percentage ofCD 3 +, CD 4 ÷, CD 8 +, CD 57 ÷ and CD 16 ÷ lymphocytes in the peripheral blood, bone marrow and lymph nodes 
of five B-CLL patients and five normal donors. Note that the tonsils do not originate from the same donors as the peripheral blood 
and bone marrow 
P ST Peripheral blood Bone marrow Lymph node 
CD3 CD4 CD8 CD57CD16 CD3 CD4 CD8 CD57CD16 CD3 CD4 CD8 CD57CD16 
1 IV a 1.5 0.7 0.5 1.1 0.4 2.0 1.2 0.6 1.0 0.2 2.5 1.7 0.3 1.0 1.0 
2 III 1.5 0.7 0.7 0.4 0.5 2.2 1.0 0.8 0.4 0.4 44.5 40.8 5.7 1.0 0.2 
3 II 6.5 3.1 2.5 2.3 0.7 4.8 3.9 1.6 1.9 0.3 11.4 8.3 3.2 2.3 0.0 
4 III 3.6 2.0 1.3 0.6 0.7 n.d. n.d. n.d.n.d, n.d. 14.9 9.4 2.4 0.7 0.2 
5 IV 2.2 1.5 0.7 2.1 0.2 n.d. n.d. n.d.n.d, n.d. 25.9 18.3 5.7 5.9 0.8 
C Tonsils 
1 80.6 60.0 23.7 3.2 4.9 54.1 44.7 23.7 0.8 2.1 52.8 22.8 5.4 1.5 0.4 
2 62.1 41.7 32.6 7.6 6.8 28.4 13.4 17.6 1.0 1.0 80.2 42.8 5.2 1.8 0.6 
3 64.6 41.5 27.0 2.3 4.0 24.5 20.5 22.6 0.2 0.7 6.9 3.8 0.9 0.5 0.0 
4 65.1 46.6 26.4 9.7 2.7 26.7 15.4 20.0 3.0 0.2 25.0 11.1 2.6 0.8 0.0 
5 72.3 47.9 26.9 4.8 8.4 45.3 29.5 24.0 2.9 0.9 23.6 10.7 4.8 1.4 0.1 
a On treatment; P, patient; C, control; ST, Rai stage 
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Fig. 2 a -d .  Relative occurrence of CD 4 ÷ (a), 
CD8 ÷ (b), HNK-1 (CD57+) (e) and CD 16 ÷ 
lymphocytes (d) in the peripheral blood (O), 
bone marrow (A) and lymph nodes ([~) of 5 
B-CLL patients (1, Rai stage IV; 2, Rai stage 
III; 3, Rai stage II; 4, Rai stage III; 5, Rai 
stage IV, on treatment) and 5 healthy con- 
trols. The results obtained from five tonsils 
are indicated in a separate column (7) as are 
the mean and standard eviation of the peri- 
pheral blood of 30 healthy donors (C). Data 
were normalized based on the percentage of 
CD 3 ÷ lymphocytes in the peripheral blood, 
bone marrow or lymph node. Note the linear 
scale of the CD 4/CD 3 versus the logarithmic 
scale of CD 8/CD 3, HNK-1/CD 3 and 
CD 16/CD 3 
Both peripheral blood and bone-marrow 
CD 57/CD 3 ratios were markedly larger in patients 
compared with the control group. Heterogeneous 
results were obtained for CD 57/CD 3 ratios in the 
lymph nodes of the patients. In two cases the 
CD 57/CD 3 ratios were within the range found in 
tonsils whereas, in the other three cases the 
CD 57/CD 3 ratios were eminently larger. 
In both patients and the control group, the 
CD 16/CD 3 ratios were lower in bone marrow com- 
pared with peripheral blood. In tonsils, CD 16 + was 
not present or was just above the detection level. In 
two of the patients the CD 16/CD 3 ratios in lymph 
nodes were clearly increased; note that both 
patients also had an enlarged CD 57/CD 3 ratio. 
Heterogeneity within the CD57 ÷ lymphoeytes 
Large differences were observed within the CD 57 + 
lymphocyte population in the different blood com- 
partments of the B-CLL patients. Apparently, dif- 
ferent subpopulations were present within the 
CD 57* population. The relative occurrence of these 
subpopulations differed between the specific blood 
compartments. This is illustrated for one patient in 
Fig. 3 where two-parameter density maps of ortho- 
gonal light scattering and FITC-conjugated CD 57 
fluorescence intensity are presented for lympho- 
cytes obtained from the peripheral blood (Fig. 3 a), 
bone marrow (Fig. 3 b), and lymph node (Fig. 3 c). 
Due to the enormous amount of malignant B-cells 
in B-CLL patients the majority of lymphocytes did 
not express the CD57 antigen. The malignant B- 
lymphocytes had low orthogonal ight-scattering 
signals, a property of normal B lymphocytes [21] 
and the lymphocytes of B-CLL patients [23]. In 
peripheral blood, the CD 57* lymphocytes showed a 
high density of the CD 57 antigen (i.e., a high fluo- 
rescence intensity) and a high orthogonal light scat- 
tering. Completely different characteristics of the 
CD 57 + lymphocytes were observed (Fig. 3 c) in the 
lymph nodes of this patient. Here the CD 57* lym- 
phocytes had a low density of the CD 57 antigen 
and a low orthogonal light scattering. In the bone 
marrow of this patient both CD57" lymphocytes 
populations could be observed (Fig. 3b). In all 
patients we found a similar heterogeneity of the 
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Fig. 3a -c .  Two density parameter maps of  orthogonal ight 
scattering (ordinate) and fluorescence intensity (abscissa) of the 
lymphocytes of  one B-CLL patient incubated with FITC- 
conjugated HNK-1 (CD 57). Lymphocytes from the peripheral 
blood a, bone marrow b and lymph node c 
CD57 ÷ lymphocyte population. In contrast, the 
CD 57 ÷ lymphocytes in normal bone marrow aspira- 
tes and tonsils all had a high orthogonal light scat- 
tering and a high fluorescence intensity. 
Discussion 
Decreased CD 4/CD 8 ratios have often been found 
for B-CLL patients [2,8,14-16,19]. We have 
shown in a previous study that this is due to an 
increased number of CD 8* cytotoxic lymphocytes 
[22]. A hypothesis we have put forward is that in 
B-CLL patients the cytotoxic lymphocytes are in- 
volved in an active resistance of the immune system 
against malignant B lymphocytes. The present 
study was therefore primarily concerned with an 
analysis of lymphocyte subsets, expressing cytotoxic 
surface markers, in the peripheral blood, bone mar- 
row and lymph nodes of B-CLL patients. To be sig- 
nificant in the defense against leukemic ells, cyto- 
toxic lymphocytes have to be present at tumor sites 
such as bone marrow and the lymph nodes involved 
of the patients. 
In this study, we show that in the peripheral 
blood of untreated B-CLL patients, the absolute 
numbers of cytotoxic lymphocyte subpopulations 
(i.e., CD 8b ÷, CD 16 ÷, CD 57 ÷) were significantly in- 
creased (Fig. 1 a -  c) compared with healthy donors. 
By means of two-color immunofluorescence it was 
shown that the majority of the cytotoxic lympho- 
cytes showed relatively high orthogonal light scat- 
tering indicative of cytoplasmatic granularity and 
coexpressed CD 3, CD 8, CD 16 and CD 57. The lat- 
ter implies that the majority of cells involved do not 
belong to the "classic" NK cells. The increase in ab- 
solute numbers of cytotoxic lymphocyte subpopula- 
tions was less pronounced in patients with stable 
disease. In successfully treated patients, however, 
the absolute numbers of cytotoxic lymphocytes were 
within the normal range for CD 57 ÷ and cytotoxic 
CD 8b ÷ lymphocytes and were even decreased for 
CD 16 ÷ cells. Whether this is caused by the cytotoxic 
agents used in the therapy or by the reduction of 
tumor mass is of interest but not known. 
Our observation that the absolute number of 
cytotoxic lymphocytes was increased in B-CLL pa- 
tients indicates that, in principle, there is a great 
potential for active cytotoxic function in the periph- 
eral blood of B-CLL patients. In addition, we ob- 
served a strong reaction of the immune system, 
especially in the lymph nodes. This was revealed by 
a relative increase in the CD 3 + lymphocytes in the 
enlarged lymph nodes in comparison with the 
peripheral blood or bone marrow (Table 1). 
The composition of the non-malignant lympho- 
cyte populations in the lymph nodes, however, was 
quite different compared with the peripheral blood. 
Surprisingly, the dominant population in the lymph 
nodes was CD 4* lymphocytes (Fig. 2). In fact, the 
CD 4/CD 3, CD 8/CD 3, CD 57/CD 3 and CD 16/ 
CD 3 ratios in the lymph nodes were all inverted 
when compared with the peripheral blood (Fig. 2). 
The relative number of CD4 + lymphocytes in 
the lymph nodes was also increased when compared 
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with the normal values found in tonsils. Knowledge 
of the actual function of the CD 4 ÷ lymphocytes is 
of considerable interest since they could be involved 
in stimulating the proliferation of malignant cells 
or actually "helping" to defend the system against 
the malignant cells. 
In the tonsils and in three of the patients no 
CD 16 + cells could be detected. The CD8/CD3 
ratios in the lymph nodes were within the CD8/ 
CD 3 range found in the controls. The CD 57/CD 3 
ratios in lymph nodes were still larger in three of the 
five patients compared with the controls (Fig. 2). 
A further characterization f the CD 57 + lym- 
phocytes howed the existence of two populations 
of CD 57 ÷ lymphocytes in the B-CLL patients. As in 
normal donors, the peripheral blood CD 57 + lym- 
phocytes have a high density of CD 57 antigen and 
a high orthogonal light-scattering signal [21]. The 
same characteristics were found for the CD 57 ÷ lym- 
phocytes as found in the tonsils and bone marrow 
of the controls: In contrast, he CD 57 ÷ lymphocytes 
found in the lymph nodes of all patients had a low 
density of CD57 receptors and a low intensity of 
orthogonal light scattering. In the bone marrow of 
the patients, both normal and abnormal popula- 
tions were observed. Whether these observations 
could be explained by the existence of two distinct 
populations of CD57 + lymphocytes or reflect the 
different maturational stages of CD57 ÷ lympho- 
cytes is unknown. 
The absolute increase in CD8b ÷, CD57 ÷ and 
CD 16 ÷ lymphocytes in the peripheral blood of 
B-CLL patients uggests a causal relation with the 
accumulation of malignant B lymphocytes. That 
these cytotoxic lymphocyte populations are respon- 
sible for the defense against malignant B lympho- 
cytes is an oversimplification. The majority of lym- 
phocytes involved in the enormous immune response 
observed at the actual tumor sites, i.e., bone mar- 
row and especially l mph nodes, expressed the CD 4 
antigen, but not the CD8, CD57 or CD 16 anti- 
gens. Furthermore, the CD 57 ÷ lymphocytes in the 
lymph nodes of the patients were found to be ab- 
normal. Although major changes in the lymphocyte 
populations can be found in the different blood 
compartments of B-CLL patients compared with 
normal donors, to actually understand the immune 
response voked by the malignant cells will require 
studies of the function and interaction of the dif- 
ferent lymphocyte populations at the tumor sites. 
One important observation that we made when 
studying the different blood compartments in both 
normal and patients is that the relative occurrence 
of cell subpopulations in the peripheral blood does 
not reflect he actual situation in the bone marrow 
and lymph nodes. Moreover, one must determine 
the occurrence of the lymphocyte populations at 
the site of interest o obtain the local distribution 
of the lymphocyte populations. Furthermore, one 
must realize that the absolute number of lympho- 
cytes in peripheral blood is only a small fraction of 
the total amount of lymphocytes. A small change in 
the amount of a lymphocyte subpopulation i a 
major blood compartment can cause a significant 
change in the concentrations of these lymphocytes 
in the peripheral blood. 
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